Merriman Curhan Ford initiates coverage on Halozyme (Nasdaq: HALO) with a Buy. Price target $5.

Merriman analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE